AtriCure stock price target raised to $53 from $51 at Canaccord Genuity

Published 30/07/2025, 13:16
AtriCure stock price target raised to $53 from $51 at Canaccord Genuity

Investing.com - Canaccord Genuity raised its price target on AtriCure (NASDAQ:ATRC) to $53.00 from $51.00 on Wednesday, while maintaining a Buy rating on the medical device company’s stock. According to InvestingPro analysis, AtriCure appears to be currently undervalued based on our proprietary Fair Value model.

The firm’s decision follows AtriCure’s strong second-quarter performance, with revenue reaching $136.1 million, representing 16.5% year-over-year growth on a constant currency basis. This exceeded both Canaccord’s estimate of $130.7 million and the consensus forecast of $130.2 million. InvestingPro subscribers have access to over 30 additional financial metrics and exclusive ProTips that provide deeper insights into AtriCure’s growth trajectory.

AtriCure demonstrated improved profitability with adjusted EBITDA of $15.4 million, surpassing Canaccord’s projection of $11.1 million and consensus estimates of $10.0 million. The company also generated $17.9 million in cash flow and reported adjusted earnings per share of $(0.02), better than the expected $(0.14).

Management raised its guidance midpoint beyond the second-quarter beat, with growth expected from recently launched products in Pain Management and Appendage Management. While PFA (pulsed field ablation) continues to pressure minimally invasive ablation procedures, the company’s open appendage management, open ablation, and pain management segments are driving results. For a comprehensive analysis of AtriCure’s growth potential and competitive position, visit InvestingPro for exclusive insights and detailed financial metrics.

Canaccord’s price target increase reflects both comparable group multiple expansion and increased expectations for AtriCure, with analysts noting the company is "uniquely positioned to treat longstanding persistent Afib patients with EPi-Sense," which they project will return to growth by early 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.